PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.98%
R&D growth while GNPX reduces spending. John Neff would investigate strategic advantage.
58.15%
G&A growth while GNPX reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.40%
Operating expenses growth while GNPX reduces costs. John Neff would investigate differences.
20.40%
Total costs growth while GNPX reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
2.78%
D&A growth while GNPX reduces D&A. John Neff would investigate differences.
-20.82%
EBITDA decline while GNPX shows 36.60% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Operating income decline while GNPX shows 36.56% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
97.30%
Other expenses growth while GNPX reduces costs. John Neff would investigate differences.
-19.78%
Pre-tax income decline while GNPX shows 36.55% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.78%
Net income decline while GNPX shows 36.55% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
12.20%
EPS growth below 50% of GNPX's 42.63%. Michael Burry would check for structural issues.
12.20%
Diluted EPS growth below 50% of GNPX's 42.63%. Michael Burry would check for structural issues.
35.62%
Share count reduction below 50% of GNPX's 10.53%. Michael Burry would check for concerns.
35.62%
Diluted share reduction below 50% of GNPX's 10.46%. Michael Burry would check for concerns.